Investigators develop novel treatment for T-cell leukemias and lymphomas
HMN 2024 – Anti-TRBC1 CAR T cell activity is limited by normal T cell-mediated killing of the CAR T cells. Credit: Nature (2024). DOI: 10.1038/s41586-024-07233-2 A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found […]